Drug intelligence / Profile preview

Dance-501

Development stage
Approved
Lead developer
Aerami Therapeutics
Modality
Recombinant Proteins and Enzymes
Administration
Inhalation
01

Overview

Dance-501 is a preservative-free, recombinant human insulin formulated as a high-purity liquid for pulmonary delivery via a proprietary soft-mist, electronic vibrating-mesh inhaler developed by Dance Biopharm (now Aerami Therapeutics) for prandial treatment of diabetes, primarily type 2 diabetes.[2][3][4][8][11][14] The drug–device combination generates a gentle, aqueous aerosol of insulin that is rapidly absorbed through the lungs, producing glucodynamic effects comparable to subcutaneous insulin lispro but with a faster onset of action and greater early glucose-lowering effect in clamp studies.[3][4][8][9] Phase 2 crossover trials have shown linear dose–response, predictable pharmacokinetics and pharmacodynamics, and good pulmonary tolerability, with no cough or acute changes in lung function reported, supporting its potential as an alternative to rapid‑acting injectable insulin for mealtime glucose control.[2][3][4][8][9]

Brand names
ActrapidActrapid HumanNovolin RHumulin RInsuman Rapid
Other names
inhaled human insulinhuman insulin inhalation solutioninsulin inhalation solution AER 501
02

Targets

INSR (Insulin receptor)

Beyond the preview

Go deeper on Dance-501.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dance-501.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call